Silexion Therapeutics (SLXN) Projected to Post Quarterly Earnings on Tuesday

Silexion Therapeutics (NASDAQ:SLXN) is anticipated to announce its results before the market opens on Tuesday, March 17th. Analysts expect the company to announce earnings of ($1.17) per share for the quarter.

Silexion Therapeutics Price Performance

Shares of SLXN stock opened at $1.61 on Monday. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.97 and a quick ratio of 3.97. The company has a market capitalization of $5.02 million, a PE ratio of -0.14 and a beta of -0.04. The firm’s 50-day moving average is $1.85 and its two-hundred day moving average is $2.91. Silexion Therapeutics has a 12 month low of $1.42 and a 12 month high of $22.36.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on SLXN shares. Wall Street Zen lowered shares of Silexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Zacks Research upgraded Silexion Therapeutics to a “hold” rating in a research report on Tuesday, December 16th. Finally, Litchfield Hills Research assumed coverage on Silexion Therapeutics in a research note on Monday, December 15th. They set a “buy” rating for the company. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $75.00.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.